Tags : River Blindness

Medicines Development for Global Health’s (MDGH) Moxidectin Receives FDA Approval

Shots: The approval is based on two clinical studies results assessing Moxidectin vs SoC Ivermectin in patients with river blindness aged ≥ 12 yrs. The study resulted in meeting 1EPswith superiority of Moxidectin vs SoC Ivermectin and resulted in suppression of microfilariae in the skin Moxidectin (8mg, PO) is macrocyclic lactone anthelmintic medication active against […]Read More